Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618306 | 0.75 | ALDH1A1 (0.33) | KDM4EALDH1A1LMNA | |
| SCHEMBL30517367 | 0.73 | EEF2K (0.46) | KDM4EALDH1A1LMNA | |
| SCHEMBL12301200 | 0.73 | EEF2K (0.46) | KDM4EALDH1A1LMNA | |
| SCHEMBL28235966 | 0.73 | EEF2K (0.46) | KDM4EALDH1A1LMNA | |
| SCHEMBL1276978 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1LMNA | |
| Bromide SCHEMBL28595717 | 0.72 | NPC1 (0.46) | KDM4EALDH1A1LMNA | |
| Fluoride SCHEMBL30330542 | 0.72 | EEF2K (0.45) | KDM4EALDH1A1LMNA | |
| Fluoride SCHEMBL30212815 | 0.72 | EEF2K (0.45) | KDM4EALDH1A1LMNA | |
| Fluoride SCHEMBL30330450 | 0.72 | EEF2K (0.45) | KDM4EALDH1A1LMNA | |
| Water SCHEMBL28587389 | 0.72 | EEF2K (0.45) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | DUT 1140/4885HTR1B 4877/4885NR2E1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.